Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances i
Post# of 420
(Total Views: 206)
Posted On: 04/18/2022 3:49:23 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria
- Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls
- The company hopes to affirm this in the NIC-H22-1 human nicotine study as their DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn
- Lexaria has separately announced new agreements with Altria that will see the company receive a fee to provide certain DehydraTECH powder-based nicotine formulations that Altria will evaluate
- The company hopes that this, coupled with the human clinical study, will confirm that purified nicotine with DehydraTECH leads to better oral tissue absorption and reduced negative experiences relative to existing brands
Lexaria Bioscience (NASDAQ: LEXX) has made a name for itself as a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) technology, promotes fast-acting, less expensive, and more effective oral drug delivery, proven through in vivo, in vitro, and human clinical testing.
So far, Lexaria has filed for patent protection for specific delivery of vitamins, NSAIDs, estrogen, cannabinoids, testosterone, PDE5 inhibitors, and terpenes, among others. However, one product that stands out is nicotine.
Since developing DehydraTECH back in 2014, the company has been pushing for its application to most oral forms of nicotine, including but not limited to tablets, capsules, pouches, sprays, gums, pills, and lozenges. Earlier this year, the company was granted a new Australian patent that recognized DehydraTECH’s superiority in oral nicotine delivery, including in free base nicotine, nicotine salts, polymer resins of nicotine, and other forms of nicotine complexes (https://nnw.fm/4PFck).
In 2021, Lexaria demonstrated that oral nicotine pouches using DehydraTECH technology were 10 to 20 times faster in reaching peak nicotine delivery to the bloodstream than controls, taking advantage of the new oral nicotine patent award. This animal study NIC-A21-1 showed the technology’s potential, which the company hopes will be affirmed in the NIC-H22-1 human nicotine study set to begin dosing in the summer of 2022 (https://nnw.fm/sFKNL).
In another significant milestone for the company’s nicotine field of study, Lexaria announced having entered into new agreements with Altria Client Services, LLC. These agreements will see Lexaria receive a fee to provide certain DehydraTECH powder-based nicotine formulations, which will be evaluated by Altria (https://nnw.fm/uyFIn).
With this, coupled with the NIC-H22-1 study, Lexaria hopes to evidence that purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences, particularly when compared to brands that are currently in the market.
In 2018, the global smokeless tobacco products market was valued at $13.6 billion. By 2025, it is projected that this industry will have posted a 7.2% annual growth. Specifically, the global market for oral nicotine pouches stood at $2.33 billion in 2020. Furthermore, it is projected that by 2027, this sector will be valued at $21.84 billion, representing a CAGR of 30.7%.
Lexaria plans to capitalize on this growth and the company’s management is confident that the investments made thus far will pay off significantly as time progresses.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls
- The company hopes to affirm this in the NIC-H22-1 human nicotine study as their DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn
- Lexaria has separately announced new agreements with Altria that will see the company receive a fee to provide certain DehydraTECH powder-based nicotine formulations that Altria will evaluate
- The company hopes that this, coupled with the human clinical study, will confirm that purified nicotine with DehydraTECH leads to better oral tissue absorption and reduced negative experiences relative to existing brands
Lexaria Bioscience (NASDAQ: LEXX) has made a name for itself as a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) technology, promotes fast-acting, less expensive, and more effective oral drug delivery, proven through in vivo, in vitro, and human clinical testing.
So far, Lexaria has filed for patent protection for specific delivery of vitamins, NSAIDs, estrogen, cannabinoids, testosterone, PDE5 inhibitors, and terpenes, among others. However, one product that stands out is nicotine.
Since developing DehydraTECH back in 2014, the company has been pushing for its application to most oral forms of nicotine, including but not limited to tablets, capsules, pouches, sprays, gums, pills, and lozenges. Earlier this year, the company was granted a new Australian patent that recognized DehydraTECH’s superiority in oral nicotine delivery, including in free base nicotine, nicotine salts, polymer resins of nicotine, and other forms of nicotine complexes (https://nnw.fm/4PFck).
In 2021, Lexaria demonstrated that oral nicotine pouches using DehydraTECH technology were 10 to 20 times faster in reaching peak nicotine delivery to the bloodstream than controls, taking advantage of the new oral nicotine patent award. This animal study NIC-A21-1 showed the technology’s potential, which the company hopes will be affirmed in the NIC-H22-1 human nicotine study set to begin dosing in the summer of 2022 (https://nnw.fm/sFKNL).
In another significant milestone for the company’s nicotine field of study, Lexaria announced having entered into new agreements with Altria Client Services, LLC. These agreements will see Lexaria receive a fee to provide certain DehydraTECH powder-based nicotine formulations, which will be evaluated by Altria (https://nnw.fm/uyFIn).
With this, coupled with the NIC-H22-1 study, Lexaria hopes to evidence that purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences, particularly when compared to brands that are currently in the market.
In 2018, the global smokeless tobacco products market was valued at $13.6 billion. By 2025, it is projected that this industry will have posted a 7.2% annual growth. Specifically, the global market for oral nicotine pouches stood at $2.33 billion in 2020. Furthermore, it is projected that by 2027, this sector will be valued at $21.84 billion, representing a CAGR of 30.7%.
Lexaria plans to capitalize on this growth and the company’s management is confident that the investments made thus far will pay off significantly as time progresses.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼